Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice

Bruton tyrosine kinase (BTK) inhibitors represent an important therapeutic advancement for B cell malignancies. Ibrutinib, the first-in-class BTK inhibitor, is approved by the US FDA to treat patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and mantle cell lymphoma...

Full description

Bibliographic Details
Main Authors: Susan M. O’Brien, Jennifer R. Brown, John C. Byrd, Richard R. Furman, Paolo Ghia, Jeff P. Sharman, William G. Wierda
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Oncology
Subjects:
acalabrutinib
adverse events
Bruton tyrosine kinase inhibitor
chronic lymphocytic leukemia
ibrutinib
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.720704/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.720704/full

Similar Items